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Many studies have suggested the hypothesis that the plasminogen activator (PA) system and the matrix metalloproteinase (MMP) system,
either separately or in combination, may provide the proteolytic activity that is required for rupture of the follicular wall at the time of ovulation.
Our recent studies on ovulation in plasminogen (plg)-deficient mice have, however, shown that plasmin is not required for normal ovulation,
leading us to the hypothesis that MMPs may be a more important source of proteolysis for this process. To investigate the role of MMPs and also
the possibility of a functional overlap or synergy between the MMP and PA systems during ovulation, we have studied ovulation efficiency in
wild-type and plg-deficient mice treated with the broad-spectrum MMP inhibitor galardin. We found that in both wild-type mice and heterozygous
plg-deficient (plg+/−) mice that had been treated with galardin prior to ovulation, there was a mild (18–20%) reduction in ovulation efficiency.
Surprisingly, galardin treatment of plg-deficient (plg−/−) mice only caused an additional 14% reduction in ovulation efficiency as compared to
vehicle-treated plg−/− mice. Our data therefore suggest that although MMPs may play a role in degradation of the follicular wall, they may not be
obligatory for ovulation. In contrast to previous studies on tissue remodeling during wound healing and placental development, we have
demonstrated that there is no obvious functional overlap or synergy between the PA and MMP systems, which has previously been thought to be
essential for the ovulatory process.
© 2006 Elsevier Inc. All rights reserved.Keywords: Ovulation; Plasminogen activators; Matrix metalloproteinases; MiceIntroduction
Ovulation, the liberation of mature ova, is a fundamental
process in mammals. It is required for the propagation of all
mammalian species (Espey and Lipner, 1994). The ovulatory
process involves follicular rupture, which is triggered by a surge
of luteinizing hormone (LH) released from the pituitary, and
it recurs in every reproductive cycle in female mammals
(Erickson, 1986; Espey and Lipner, 1994). For breakdown of
the follicular wall to take place, an extensive proteolytic degra-
dation of basement membranes and connective tissues making
up the follicular wall is required. Over the past 3 decades, many⁎ Corresponding author. Fax: +46 90 7869795.
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doi:10.1016/j.ydbio.2006.03.046studies in both rodents and primates have suggested that two
protease families, the plasminogen activator (PA) system and the
matrix metalloproteinase (MMP) system, may play an important
role in the degradation of the ovarian follicular wall (for refer-
ences and reviews, see Beers et al., 1975; Strickland and Beers,
1976; Tsafriri and Reich, 1999; Liu et al., 1998; Curry and
Osteen, 2001; Ny et al., 2002).
Although a substantial body of indirect evidence obtained
from several species has suggested that plasmin has a role in
ovulation, our studies in plasminogen (plg)-deficient (plg−/−)
mice have provided genetic evidence that the absence of plasmin
has only a mild effect on ovulation, manifested as an insig-
nificant (13%) reduction in ovulation efficiency (Ny et al.,
1999). This marginal reduction in ovulation efficiency may also
be caused by delayed maturation of the plg−/− mice, seen as
reduced body and ovarian weight (Ny et al., 1999). Based on this
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may participate in the ovulatory process in mice, the role it plays
is not indispensable. MMPs are also widely expressed in the
ovary during the periovulatory period and many reports suggest
that they may play an important role in rupture of the follicular
wall during ovulation (for reviews, see Woessner, 1991; Tsafriri
and Reich, 1999; Curry and Osteen, 2001; Ny et al., 2002). In
other biological or pathological processes requiring proteolysis,
including angiogenesis, tumor metastasis, mammary gland in-
volution, adipose tissue development, wound healing, and pla-
cental development, a coordinated function between the PA and
the MMP systems has been shown to be required (Saksela and
Rifkin, 1988; Mignatti and Rifkin, 1993; Khokha et al., 1995;
Lund et al., 1999; Lijnen et al., 2002; Ny et al., 2002; Solberg et
al., 2003). For example, when MMP activities were effectively
suppressed in plg−/− mice by treatment with the synthetic MMP
inhibitor galardin (GM6001), the processes of wound healing
(Lund et al., 1999) and placental development (Solberg et al.,
2003) were completely blocked. Plasminogen deficiency alone,
or galardin treatment alone, had much less effect. The pro-
nounced synergism indicates that one or more proteolytic events
are essential for these processes, and that these critical pro-
teolytic events can be the result of either plasmin activity or
MMP activity (Lund et al., 1999; Solberg et al., 2003). Inspired
by these studies, we wanted to test whether there is a functional
overlap or synergy between plasmin and MMPs in follicular
rupture during ovulation.We thus studied the effect of the broad-
spectrum MMP inhibitor galardin on ovulation in wild-type and
plg−/− mice.
Materials and methods
Materials
Pregnant mare serum gonadotropin (PMSG) and human chorionic
gonadotropin (hCG) were purchased from Sigma (St. Louis, MO). McCoy's
5A medium (modified, without serum) was purchased from Invitrogen
(Gaithersburg, MD). The gelatinolytic activity assay and purified human
MMP-2 were purchased from Roche Molecular Biochemicals (Mannheim,
Germany). S-2251, a chromogenic substrate for plasmin activity, was purchased
from Chromogenix (Mölndal, Sweden). Ninety-six-well plates (Nunclon) were
obtained from Nunc A/S (Roskilde, Denmark), and the microtiter plate reader
Multiscan RC was from Labsystems (Stockholm, Sweden).
Animals
C57BL/6 wild-type mice were obtained from Bomholtgård Breeding and
Research Center (Ry, Denmark). The plg-deficient mice used were as previously
described (Ploplis et al., 1995). The plg−/− mice, and also their plasminogen
heterozygous (plg+/−) and plasminogen wild-type (plg+/+) F2 littermates, were
obtained from plg+/− × plg+/− breeding (backcrossed 10 generations to C57BL/
6). The mice were genotyped as previously described (Ny et al., 1999). The mice
were kept on a 12-h light/12-h dark cycle with the light cycle initiated at 06.00 h,
and were fed chow and water ad libitum. Experimental protocols were approved
by the regional ethical committee of Umeå University.
Gonadotropin-induced ovulation in mice
To induce synchronized follicular growth and ovulation, immature 25-day-
old female mice were injected i.p. with 1.5 IU of PMSG to stimulate follicular
development, and with 5 IU hCG 48 h later to induce ovulation. Ovulation
normally takes place 10–12 h after hCG treatment (Rugh, 1990; Ny et al., 1999).Animals were sacrificed by cervical dislocation at selected time points after
administration of hCG. To record the number of ova, the mice were sacrificed
20 h after hCG treatment and ova in the oviducts were counted as previously
described (Leonardsson et al., 1995; Ny et al., 1999). Body weights and ovarian
weights were also recorded.
Treatment with MMP inhibitor
The peptide hydroxamate MMP inhibitor galardin (Grobelny et al., 1992)
was dissolved in 4% (w/v) carboxymethyl cellulose in 0.9% saline, which gave a
final concentration of 20 mg/ml. At the time of hCG injection, galardin (100 mg/
kg body weight) was administrated i.p. This dosage of galardin has been proven
to effectively inhibit MMP activities and to disrupt wound healing and placental
development in plg-deficient mice (Lund et al., 1999; Solberg et al., 2003). The
same volumes of vehicle (carboxymethyl cellulose) were injected as controls. In
a separate experiment, 200 mg/kg body weight of galardin was also admin-
istered during follicular development at 3 time points: at the time of PMSG
administration, 24 h after PMSG administration, and at the time of hCG
administration. The same volume of vehicle (carboxymethyl cellulose) was used
as control.
Preparation of ovarian extract
Ovaries were dissected free of adhering tissue, washed several times in cold
McCoy's 5A medium, and kept at −80°C for further analysis. To ensure that the
mice responded properly to hormone treatment, only mice with a body weight of
10 g ormore andwith ovaries with a total weight of 4mg ormore were used in the
experiments. Ovaries (n = 8–16) were transferred to a pre-cooled homogenizer
and extracts were prepared on ice, followed by centrifugation at 14,000 rpm for
10 min at 4°C. The supernatants were then collected and protein concentrations
were measured using the bicinchoninic acid (BCA) protein assay.
Gelatin zymography
Ovarian extracts (15 μg of total protein) were analyzed by gelatin
zymography in 7.5% SDS-polyacrylamide (SDS-PAGE) gels containing
1.8 mg/ml gelatin, as previously described (Masure et al., 1990). After elec-
trophoresis, the gels were incubated in 2.5% (v/v) Triton X-100 for 2 × 20 min to
remove SDS, and then incubated in a buffer containing 50 mM Tris, pH 7.5,
5 mM CaCl2, 1% Triton X-100 and 0.02% NaN3 for 50 h.
Gelatin substrate assay
Aliquots of 15 μg of ovarian extract were tested for gelatinolytic activity,
using anMMP assay detecting degradation of biotinylated gelatin. The assaywas
performed according to the manufacturer's instructions (Roche). Briefly, MMPs
in ovarian extracts were activated immediately prior to use by 2.5 mM
aminophenylmercuric acetate (APMA) at pH 7.0–7.5. Ovarian extracts
containing activated MMPs were incubated at 37°C for 4 h in 50 mM Tris,
1 mM CaCl2, 0.05% (v/v) Triton X-100, pH 7.5, with biotin-labeled gelatin. The
sample was then transferred to a streptavidin-coated microtiter plate and
incubated at room temperature for 30min. After washing, the plate was incubated
with a streptavidin–peroxidase conjugate, which would bind to remaining free
biotin residues on the biotin-labeled gelatin. Finally, the remaining biotin
residues could be detected after incubation with a color substrate (ABTS®).
Absorbance at 405 nm was measured for 30 min at 5 min intervals with a
microtiter plate reader. In this assay, high gelatinase activity yields low
absorbance, while low activity results in high absorbance.
In situ gelatinase zymography
In situ gelatinase zymography was performed on 10-μm cryosections as
described by Leco et al. (2001). Briefly, the sections were covered with a layer of
0.5% low melting point agarose gel containing substrate buffer and 100 μg/ml
fluorescein-conjugated DQ gelatine from Molecular Probes Inc. (Eugene, OR),
overlayed with coverslips, and incubated in a humidity chamber at 37°C for
16 h. As a negative control, 10 mM EDTA, which chelates Zn2+ and Ca2+, was
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DC300F digital camera attached to a Leica DM LB microscope (Leica, Wetzlar,
Germany).Fig. 1. Galardin inactivates MMPs in ovarian extracts. (A) Ovarian gelatinolytic
activity was inhibited by galardin in vitro. Twenty-five-day-old wild-type
(C57BL/6) mice, previously treated with PMSG and hCG, were sacrificed 4 h
after hCG treatment and ovarian extract was prepared. Fifteen-μg aliquots of the
ovarian extract were separated by SDS-PAGE and the gel strips were then
analyzed for gelatinolytic activity by gelatin zymography in the absence or
presence of increasing amounts of galardin. The migration patterns of the pro-
forms of MMP-2 and MMP-9 are indicated with arrows. (B) Ovarian
gelatinolytic activity was inhibited by galardin in vivo. Twenty-five-day-old
wild-type (C57BL/6) mice were similarly injected with PMSG and hCG as in
panel A. At the time of hCG injection, 100 mg galardin per kg of body weight or
the same volume of vehicle was injected into the mice. Six hours after hCG
treatment, the mice were sacrificed and ovarian extracts were prepared and
analyzed by gelatinolytic substrate assay. The sample containing a mixture of
extracts from galardin- and vehicle-treated mice in a 1:1 ratio was also analyzed
in this assay. The height of the bars represents mean ± SEM of relative
gelatinolytic activity, where the activity level from extract of vehicle-treated
control mice has been set to 100%.Results
In vitro inhibition of ovarian MMP activities by the
broad-spectrum MMP inhibitor galardin
To test whether MMP activities detected in ovarian extracts
can be efficiently inhibited by galardin in vitro, we induced
follicular growth and ovulation in immature female mice and
collected pre-ovulatory ovaries for preparation of ovarian ex-
tracts. Aliquots of 15 μg of ovarian extracts were analyzed by
gelatin zymography to estimate the activities of MMP-2 and
MMP-9 (gelatinase A and B, respectively) in the ovaries. As
shown in Fig. 1A (lane 1), ovarian extracts prepared from
ovaries just prior to ovulation contained high levels of MMP-2,
and MMP-9 to a lesser extent. Both gelatinases appeared to be
mostly in their latent pro-forms, as the molecular weights of their
activities were reduced by approximately 10 kDa following
treatment with the MMP-activating agent aminophenylmercuric
acetate (APMA) (data not shown) (Hägglund et al., 1999). As
shown in Fig. 1A, lanes 2–5, addition of increasing amounts of
galardin (0.016 μM to 2 μM) to the ovarian extracts efficiently
inhibited the activities of both MMP-2 and MMP-9. The
detectable gelatinolytic activity was completely abolished by
0.4 μM galardin, as measured by gelatin zymography (Fig. 1A,
lane 4). As a control, full inhibition of the gelatinase activity was
also observed when 5 mM EDTA was included as a chelating
reagent to block MMP activity by neutralizing Ca2+ and Zn2+ in
the assay buffer (data not shown).
In vivo inhibition of ovarian MMPs by galardin treatment
Previous reports have showed that i.p. injection of 100 mg
galardin per kg of body weight effectively suppresses MMP
activity in mice in vivo (Gijbels 1994; Alexander et al., 1996;
Lund et al., 1999). This is a much higher dose as compared to the
concentration of galardin we used in our in vitro experiment
(Fig. 1). To test whether this dose of galardin is sufficient to
inhibit MMP activities in the ovary, we injected galardin into
wild-type C57BL/6 mice and measured the gelatinase activities
in their ovarian extracts after galardin treatment.
Mice were induced to ovulate with PMSG and hCG, and at
the same time as hCG treatment, galardin or vehicle was in-
jected. Six hours after galardin or vehicle injection, ovarian
extracts were prepared and treated with APMA to convert pro-
MMPs to their active forms before the gelatinolytic activity was
determined (Hägglund et al., 1999). As shown in Fig. 1B,
ovarian extracts from galardin-treated mice contained less than
5% of the gelatinolytic activity found in extracts from vehicle-
treated mice. When ovarian extracts from vehicle-treated mice
and galardin-treated mice were mixed in a 1:1 ratio, still less than
5% of the gelatinolytic activity was measured in the mixture
(Fig. 1B). This indicates that the amount of galardin in the
ovarian tissue from inhibitor-treated mice was in excess, andinhibited all additional gelatinolytic activity present in the
untreated half of the sample.
To test further whether galardin can inhibit MMPs in follicles
in vivo, in situ gelatinase zymography was performed on ovary
sections from mice 6 h after hCG/galardin treatment. Gelatinase
activity was detected in the theca tissue of the follicles from
vehicle-treated mice (Fig. 2A, large arrow). In ovaries from
galardin-treated mice, only faint gelatinolytic activity was
detected (Fig. 2B, small arrow). As a negative control, it was
also possible to inhibit the gelatinase activity by the addition of
10 mM EDTA to the zymography gel (Fig. 2C, arrowhead).
Fig. 2. In situ gelatinase activity is suppressed in ovaries from galardin-treated wild-type C57BL/6 mice. Twenty-five-day-old female wild-type (C57BL/6) mice were
injected with PMSG and hCG to induce ovulation. At the time of hCG injection, 100 mg galardin per kg of body weight or same volume of vehicle was injected. The
mice were sacrificed 6 h after hCG injection and in situ gelatinase zymography was performed on 10-μm frozen sections. Gelatinolytic activity appears as bright green
fluorescence. The pictures show representative results from vehicle-treated mice (A), galardin-treated mice (B), and also galardin-treated mice with 10 mM EDTA
added to the substrate buffer for in situ zymography (C).
Table 1
Gonadotropin-induced ovulation in galardin-treated wild-type C57BL/6 mice
Genotype Inhibitor
treatment
No. of
mice
No. of ova
per mouse
Reduced
ovulation
efficiency
P value
C57BL/6 Vehicle 23 8.8 ± 1.8
C57BL/6 Galardin 26 7.0 ± 1.5 20% 0.007
Immature 25-day-old female wild-type (C57BL/6) mice were injected
intraperitoneally with 1.5 IU of PMSG to stimulate follicular development,
and 48 h later with 5 IU hCG to induce ovulation. At the same time that hCGwas
injected, 100 mg galardin per kg body weight or the same volume of vehicle was
also injected into the mice. Animals were sacrificed 20 h after hCG treatment,
and the number of ova in the oviduct was recorded. Numbers of ova per mouse
represent mean ± SD and the reduction in ovulation efficiency represents
galardin-treated vs. vehicle-treated mice.
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spectrum MMP inhibitor. In addition, they indicate that the
inhibitor reaches the follicles when used according to our
protocol.
Ovulation efficiency in galardin-treated mice
We next examined the ovulation efficiency in both wild-type
and plg-deficient mice in the presence and absence of galardin.
Ovulation was induced by gonadotropins as described previ-
ously, and galardin or vehicle was injected at the same time as the
hCG injection. Ovulation efficiency was then determined by
counting the number of ova in the oviduct 20 h after the hCG
injection, by which time ovulation is complete (Leonardsson et
al., 1995; Ny et al., 1999). Wild-type C57BL/6 mice were first
used to determine the optimal dose of inhibitor and the time point
for galardin injection. Galardin (100 mg per kg of body weight)
was injected at the same time as hCG, and 6 h before and 6 h after
hCG, and the number of ova in the oviduct was recorded. Our
data revealed that injection of 100 mg galardin per kg of body
weight at the same time as hCG injection or 6 h before hCG gave
equal reductions in ovulation efficiency. In contrast, injection of
the inhibitor 6 h after hCG had no effect on ovulation efficiency
(data not shown). A double-dose of galardin (200 mg of galardin
per kg body weight), injected at the same time as hCG, did not
suppress the ovulation efficiency any further, while injection of
half the dose (50 mg of galardin per kg of body weight) caused
approximately half of the degree of suppression (data not
shown). This suggests that ovulation is suppressed by galardin
in a dose-dependent manner, and that a sufficient amount of
galardin is distributed to the ovary to obtain an optimal inhi-
bition when 100 mg galardin per kg of body weight is injected
at the same time as the hCG.
Having established the protocol for in vivo inhibition of
MMPs, we first studied the effect of galardin on ovulation in
wild-type C57BL/6 mice. As shown in Table 1, ovulation
efficiency was suppressed by 20% (P = 0.007) with galardin
treatment relative to vehicle-treated C57BL/6 mice. This mode-
rate inhibition suggests that MMPs may play a role in ovulation,but that they are not indispensable for this process. The effect of
galardin on ovulation in wild-type mice is comparable to the
13% reduction in ovulation efficiency caused by plasminogen
deficiency (Ny et al., 1999).
We then proceeded to test whether follicular rupture involves
a functional overlap between MMPs and plasmin, as seen in
previous studies in other tissues (Lund et al., 1999; Solberg et al.,
2003). Ovulation was induced in galardin-treated plg−/− mice as
well as in plg+/− and plg+/+ littermates. As shown in Table 2,
galardin treatment of plg+/+ and plg+/− mice caused a 19%
(P = 0.056) and 18% (P = 0.022) reduction in ovulation effi-
ciency, respectively, as compared to vehicle-treated plg+/+ and
plg+/− mice. Although these reductions were similar to that in
galardin-treated C57BL/6 mice (20% reduction in ovulation
efficiency, Table 1), we noticed that the 19% reduction in
ovulation efficiency in galardin-treated plg+/+ mice was not sta-
tistically significant (P = 0.056), which is different from the
significant reduction in ovulation efficiency induced by galardin
in commercial C57BL/6 mice (P = 0.007). This may have been
caused by the higher body weight variations in the plg+/− mice
that were bred in our own animal facility, which may have led to
larger standard deviations in the oocyte numbers. Surprisingly,
only a further reduction in ovulation efficiency of 14% relative to
Table 2
Gonadotropin-induced ovulation in galardin-treated plg−/− mice
Genotype Inhibitor
treatment
No. of
mice
No. of ova
per mouse
Reduced ovulation
efficiency (galardin
vs. vehicle)
P value
Plg+/+ Vehicle 26 8.8 ± 2.2
Plg+/+ Galardin 16 7.1 ± 2.2 19% 0.056
Plg+/− Vehicle 30 8.3 ± 1.8
Plg+/− Galardin 38 6.8 ± 1.9 18% 0.022
Plg−/− Vehicle 19 7.3 ± 1.6
Plg−/− Galardin 24 6.3 ± 1.9 14% 0.173
Ovulation was induced in immature 25-day-old female wild-type (plg+/+),
heterozygous (plg+/−), and plg-deficient (plg−/−) mice as described in the legend
to Table 1. One hundred mg galardin per kg body weight, or the same volume of
vehicle, was injected into the mice at the time of hCG injection. Animals were
sacrificed 20 h after hCG treatment, and the number of ova in the oviduct was
recorded. Numbers of ova per mouse represent mean ± SD and the reduction in
ovulation efficiency represents galardin-treated vs. vehicle-treated mice. The
reduction in ovulation efficiency between untreated plg−/− mice and untreated
plg+/+ mice was 17% (P = 0.039). The reduction in ovulation efficiency between
inhibitor-treated plg−/− mice and untreated plg+/+ mice was 28% (P = 0.002).
Table 3
Onset of follicular wall rupture
Genotypes Treatment No. of
mice used
No. of mice
ovulated
Percentage of
ovulated mice
C57BL/6 Vehicle 10 5 50
C57BL/6 Galardin 11 5 45
Plg+/+ Vehicle 5 3 60
Plg+/+ Galardin 6 4 67
Plg+/− Vehicle 11 5 45
Plg+/− Galardin 12 5 42
Plg−/− Vehicle 5 3 60
Plg−/− Galardin 6 3 50
Twenty-five-day-old female wild-type (C57BL/6), plg+/+, plg+/−, and plg−/−
mice were injected with PMSG and hCG to induce ovulation, as described in the
legend to Table 1. At the time of hCG injection, 100 mg galardin per kg of body
weight or the same volume of vehicle was injected. The mice were sacrificed
12 h after hCG injection, and ovaries were removed and examined for the
presence of ova in the bursa or in the oviduct, for indications of onset of
follicular rupture.
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treated with galardin. This mild reduction is comparable to the
reduction seen in galardin-treated plg+/+ or plg+/−mice (19% and
18%, respectively) (Table 2).
When the ovulation efficiencies of vehicle-treated plg+/+
mice (8.8 ova per mouse) and galardin-treated plg−/− mice (6.3
ova per mouse) were compared, a 28% reduction (P = 0.002) in
ovulation efficiencywas seen in the galardin-treated plg−/−mice.
This reduction represents the effect of combined plasminogen
deficiency and MMP inhibition on ovulation, and thus suggests
a very mild additive effect of the PA and the MMP systems on
ovulation.
Effects of galardin and plasminogen deficiency on the onset of
follicular wall rupture
In order to study whether the suppression of MMP activities
by galardin alone, or a combined MMP suppression and plas-
minogen deficiency may delay the onset of follicular wall rup-
ture, we first treated C57BL/6 wild-type mice with galardin or
vehicle at the time of hCG injection. Twelve hours after treat-
ment with hCG, the mice were sacrificed and the presence of ova
in the bursa or oviduct was investigated. As previously reported
for this model, approximately 50% of C57BL/6 mice have
started to ovulate at this time point (Ny et al., 1999). Similarly, as
shown in Table 3, 5 of 10 vehicle-treated mice, and 5 of 11
galardin-treated mice had started the ovulation process at this
time point, indicating that galardin treatment does not cause
any apparent delay in the gonadotropin-stimulated onset of
ovulation.
Previous studies have shown that the onset of follicular wall
rupture is not delayed in plg-deficient mice (Ny et al., 1999).
Thus, plasminogen deficiency alone, or galardin treatment
alone, does not appear to cause any apparent delay in onset of
follicular wall rupture. To studywhether the combined inhibition
of these two enzyme systems would cause a delay in the onset of
follicular wall rupture, ovulation was induced in plasminogenwild-type (plg+/+), heterozygous (plg+/−) and homozygous
(plg−/−) mice as described above. As shown in Table 3, similar
numbers of galardin-treated plg−/− mice and vehicle-treated
plg+/+ mice had started to ovulate 12 h after hCG treatment. A
similar percentage of mice that had started to ovulate at this time
point was also seen in the galardin- and vehicle-treated plg+/−
and plg+/+ groups of mice.
Discussion
Many previous studies in both rodents and primates have
suggested that the PA system and the MMP system may play an
important role in the degradation of the ovarian follicular wall
(Beers et al., 1975; Strickland and Beers, 1976; Liu et al., 1998;
Tsafriri and Reich, 1999; Curry and Osteen, 2001; Ny et al.,
2002). However, recent studies of ovulation in PA- and plg-
deficient mice have revealed that ovulation can occur rather
normally in the absence of a functional PA system (Leonardsson
et al., 1995; Ny et al., 1999). We and others have found that
several MMPs, including MMP-2, MMP-9, stromelysin-3,
MT1-MMP and MMP-19, are present in the mouse and rat
ovary at the time of ovulation. SomeMMPs are also upregulated
in pre-ovulatory follicles prior to ovulation, suggesting that they
may be involved in the tissue degradation that leads to follicle
rupture (Hägglund et al., 1999; Liu et al., 1998; Curry and
Osteen, 2001; Jo and Curry, 2004; Jo et al., 2004). These
findings have therefore led to the hypothesis that it is the MMP
system that may play a more prominent role in ovulation, or that
the PA and MMP systems may cooperate in this process. In this
report, we have studied the functional role of the MMP system
during gonadotropin-induced follicular development and ovu-
lation, and investigated whether the PA and MMP systems
cooperate functionally in these processes. To address these
questions, we administered the broad-spectrum hydroxamate
MMP inhibitor galardin to wild-type or plg-deficient mice. Our
data show that although galardin efficiently suppresses ovarian
MMP activity in vivo, the ovulation efficiency was only
modestly reduced (by 19%) in galardin-treated wild-type mice.
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ovulation efficiency (14%) was observed when galardin was
administered to plg−/− mice. Thus, in contrast to similar studies
with galardin in wound healing and placental development
(Lund et al., 1999; Solberg et al., 2003), there appears to be no
obvious functional overlap or synergy between the PA and the
MMP systems in the ovulatory process.
The use of young mice in this study offers the advantage that
the ovulatory process can be studied before the onset of any
pathological conditions observed later in life in plg−/− mice
(Bugge et al., 1995; Ploplis et al., 1995). Similarly to our
previous studies (Ny et al., 1999), the ovulation efficiency was
slightly reduced (by 17%) in plg−/− mice as compared to plg+/+
mice. However, this reduction may be explained by the delay in
maturation, manifested as a slightly lower body weight observed
in plg−/− mice (Ny et al., 1999). For the MMP inhibition data
presented here, the lower body weight of plg−/− mice does not
influence the interpretation of our results, as these mice were
compared to weight-matched untreated mice of similar genetic
background.
Galardin is a peptide-based zinc-chelating hydroxamate com-
pound that has a general inhibitory mechanism against the action
of all MMPs (Grobelny et al., 1992). MMP inhibitors similar or
identical to galardin have been found to effectively suppress
MMP activity in other physiological and pathological processes
involving MMPs, including embryo implantation, experimental
autoimmune encephalomyelitis, placental development, adipose
tissue development and wound healing (Alexander et al., 1996;
Gijbels et al., 1994; Lund et al., 1999; Graesser et al., 2000;
Lijnen et al., 2002; Solberg et al., 2003). The inhibitory potency
of galardin was characterized by in vitro and in vivo experi-
ments. Excess amounts of inhibitory activity were detected in
ovarian extracts frommice treatedwith galardin at 100mg per kg
of body weight. This amount of galardin caused more than 95%
inhibition of the total APMA-activated gelatinolytic activity. As
most MMP-2 and MMP-9 found in the ovary are in inactive
zymogen forms (Hägglund et al., 1999), the amount of gela-
tinolytic activity inhibited is much higher than the normal in vivo
level. As shown by in situ zymography, native gelatinolytic
activity was efficiently suppressed by our galardin treatment.
Taken together, these studies suggest that the amount of galardin
used in this study (100 mg per kg of body weight) efficiently
inhibits ovarian MMPs, and results in a mild suppression of
ovulation efficiency.
In wild-type C57BL/6, plg+/+ and also plg+/− mice, sup-
pression of ovarian MMP activity by galardin caused a modest
(18–20%) reduction in ovulation efficiency in gonadotropin-
primed mice. This reduction is smaller than that found with
similar synthetic MMP inhibitors in an in vitro perfused rat
ovary model, where treatment with synthetic MMP inhibitors
(SC 40827 and SC 44463) could suppress ovulation by up to 70–
75% (Brännström et al., 1988; Butler et al., 1991). In addition, in
the ewe, injection of an MMP-2 neutralizing antibody into the
follicular antrum blocked ovulation (Gottsch et al., 2002). These
differences may be explained by species differences between
mice, rats and sheeps. At the same time that the ovulation
blockage by in vitro perfused MMP inhibitors does reflect a rolefor MMPs in ovulation in rats (Brännström et al., 1988; Butler et
al., 1991), there may also be physiological differences between
the in vivo model used in the present study and the in vitro
perfused ovary—the in vitro perfusion model was disconnected
from the circulatory system and therefore was not accessible to
possible compensatory mechanisms.
To test the hypothesis that MMPs and plasmin cooperate and/
or functionally complement each other during ovulation, we
studied ovulation in plg−/− mice treated with galardin. Sur-
prisingly, the ovulation efficiency was reduced by only an
additional 14% when plg−/− mice were treated with galardin.
Furthermore, neither wild-type mice nor plg−/− mice displayed
any notable delay in the onset of ovulation when treated with
galardin. In a separate experiment, plg+/+, plg+/−, and plg−/−
mice were treated with one daily dose of 200 mg/kg galardin –
starting at the time of PMSG treatment– for 3 days. However, no
additional reduction in ovulation efficiency was seen in these
mice (data not shown). The lack of an obviously enhanced or
synergistic suppression of ovulation efficiencywhen plg−/−mice
were treated with galardin suggests that plasmin andMMPs may
have amuch less pronounced effect on ovulation than previously
appreciated. Alternatively, the role of MMPs and plasmin may
be effectively compensated for by other mechanisms in our
protease-deficient mouse models.
The unexpected finding in this study that neither plasmin nor
MMPs seem to be obligatory for ovulation contrasts with the
requirements on these two protease systems in wound healing
and placental development (Rømer et al., 1996; Lund et al.,
1999; Solberg et al., 2003). The observed discrepancy between
ovulation and wound healing or placental development indicates
that ovulation may be a more complex proteolytic process in-
volving other perhaps still unidentified proteases. It also indi-
cates that functional overlap between the PA and the MMP
systems is tissue-specific.
The involvement of additional proteases in ovulation could
also explain the fact that many gene-deficient mouse strains
lacking components of the PA or MMP systems are fertile, and
can therefore ovulate normally (Carmeliet et al., 1993, 1994;
Bugge et al., 1995; Ploplis et al., 1995; Dewerchin et al., 1996;
Itoh et al., 1997; Shipley et al., 1996; Soloway et al., 1996,
Wilson et al., 1997;Masson et al., 1998;Mudgett et al., 1998; Vu
et al., 1998; Ny et al., 2002). Among many possible candidates
from other protease families, it was reported that mice that are
deficient in the disintegrin metalloprotease ADAMTS-1 showed
markedly decreased ovulation efficiency, and increased per-
centage of anovulatory follicles (Shindo et al., 2000; Shozu et
al., 2005; Mittaz et al., 2004). In addition, mice lacking pro-
gesterone receptor fail to ovulate and display a deficient expres-
sion of cathepsin L and ADAMTS-1 (Robker et al., 2000). This
information indicates that ADAMTS-1may be a crucial protease
for ovulation in mice. In the current study, we have also won-
dered whether the slight reduction in ovulation efficiency in
galardin-treated mice could be due to inhibition of ADAMTS-1.
We have used western blot to measure the levels of cleaved
versican, which is an indicator of ADAMTS-1 activity (Russell
et al., 2003), in mouse ovaries after 12 h of hCG and galardin/
vehicle treatment (a time point that is just prior to ovulation).
621K. Liu et al. / Developmental Biology 295 (2006) 615–622However, our results showed that versican cleavage is not
significantly altered in ovaries from mice that were treated with
galardin (data not shown), indicating that either ADAMTS-1
activity is not significantly suppressed by galardin, or that some
other proteases can still cleave versican.
In conclusion, the data presented in this study suggest that
neither the PA system nor the MMP system – either individually
or in combination – is essential for the degradation of the
follicular wall at the time of ovulation. Our results thus challenge
the hypothesis that degradation of the follicular wall is mediated
by a proteolytic cascade generated from cooperation between the
PA and MMP systems, and they suggest that other as yet un-
identified proteases may play an important role in this process.
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